ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.38
0.74%
US Tech 100
20,810.00
1.18%
S&P 500
5,930.85
1.09%
US Dollar vs CAD
1.43226
-0.56%
Bitcoin
97,656.47
-0.11%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Mainz BioMed NV (MYNZ)

  7. Mainz BioMed NV (MYNZ) News

MYNZ

Mainz BioMed NV (MYNZ)

Mainz BioMed NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MYNZ
DateTimeSourceHeadlineSymbolCompany
12/19/20247:01AMGlobeNewswire Inc.Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening TestNASDAQ:MYNZMainz BioMed NV
12/16/20244:29PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
12/16/20244:00PMGlobeNewswire Inc.Mainz Biomed Announces Closing of $8.0 Million Follow-On OfferingNASDAQ:MYNZMainz BioMed NV
12/16/20247:00AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MYNZMainz BioMed NV
12/13/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
12/12/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MYNZMainz BioMed NV
12/12/20247:00PMGlobeNewswire Inc.Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq RulesNASDAQ:MYNZMainz BioMed NV
12/11/20248:22AMInvestorsHub NewsWireSilexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXNNASDAQ:MYNZMainz BioMed NV
12/11/20247:00AMEdgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
12/09/20244:11PMEdgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
12/09/20248:16AMEdgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
11/29/20247:45AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
11/29/20247:45AMGlobeNewswire Inc.Mainz Biomed Announces Stock SplitNASDAQ:MYNZMainz BioMed NV
11/15/20244:15PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
11/12/20248:09AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
11/12/20248:00AMGlobeNewswire Inc.Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global MarketsNASDAQ:MYNZMainz BioMed NV
11/05/20247:00AMEdgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:MYNZMainz BioMed NV
10/21/20247:15AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
10/21/20247:01AMGlobeNewswire Inc.Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:MYNZMainz BioMed NV
10/18/20243:00PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
10/09/20244:20PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
10/08/20247:01AMGlobeNewswire Inc.Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New VersionNASDAQ:MYNZMainz BioMed NV
10/03/20244:11PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
10/01/20247:01AMGlobeNewswire Inc.Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025NASDAQ:MYNZMainz BioMed NV
09/18/20247:01AMGlobeNewswire Inc.Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand AmbassadorNASDAQ:MYNZMainz BioMed NV
09/04/20243:01AMGlobeNewswire Inc.Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlertNASDAQ:MYNZMainz BioMed NV
07/25/20247:01AMGlobeNewswire Inc.Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User ConvenienceNASDAQ:MYNZMainz BioMed NV
07/09/20248:30AMAllPennyStocks.comMicro Cap Bid Up Following FDA Submission AnnouncementNASDAQ:MYNZMainz BioMed NV
07/09/20242:01AMGlobeNewswire Inc.Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening TestNASDAQ:MYNZMainz BioMed NV
07/02/20247:01AMGlobeNewswire Inc.Mainz Biomed Provides Half Year 2024 Corporate UpdateNASDAQ:MYNZMainz BioMed NV
 Showing the most relevant articles for your search:NASDAQ:MYNZ

Your Recent History

USOTC
GRLT
Grillit (PK)
USOTC
IFUS
Impact Fusion (PK)
USOTC
RDAR
Raadr (PK)
USOTC
AFFU
Affluence (PK)
USOTC
PHIL
PHI (PK)
USOTC
CBRF
CyberFuels (PK)
NASDAQ
NXPL
NextPlat
USOTC
MGON
Megola (PK)
NASDAQ
NUKK
Nukkleus
USOTC
CEOS
CeCors (PK)
USOTC
GTCH
GBT Technologies (PK)
AMEX
KULR
KULR Technology
NASDAQ
ILLR
Triller
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
MVNT
Movement Industries (PK)
USOTC
SPZI
Spooz (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads